{'fraction_non_alphanumeric': 0.02554278416347382, 'fraction_numerical': 0.007662835249042145, 'mean_word_length': 5.222222222222222, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Use of monoclonal antibodies for determining complement-binding activity of human immunoglobulins G in health and in chronic lympholeukemia].

Mouse monoclonal IgG1-antibodies (MA) against melittin were used for the investigation of human IgG-C1q binding. The ELISA method, allowing one to determine the dissociation constants of IgG-C1q complex, based on the competition of two IgG (investigating human IgG and MA, labelled by peroxidase) for C1q binding was developed. The method was used to show that IgG in 50% of cases of chronic lymphoid leukemia possessed lesser complement-binding activity than normal human IgG. This effect can be the result of screening of effector centres of immunoglobulins by ligands which appeared in the process of tissue destruction under pathology.